AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

Doctor helping patient use inhaler in office Researchers evaluated the accuracy of current strategies for assessing asthma control levels in children and the importance of considering exacerbation ...

(IN BRIEF) AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union as an add-on treatment for adults with eosinophilic granulomatosis with polyangiitis (EGPA ... Life Severe ...

Update on eosinophilic granulomatosis with polyangiitis. Allergol Int ... Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021 Sep;160(3):814-830. 9.

(Alliance News) - AstraZeneca PLC on Monday welcomed approval in the European Union of Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis. EGPA is a rare, immune-mediated ...

AstraZeneca’s (LSE: AZN) Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with ...

Earn up to 30.25 AMA PRA Category 1 Credits™. This three-day course is designed to provide radiologists with the skills and understanding necessary to interpret high-resolution CT of the chest for ...

Up to one-quarter of people with COVID-19 may experience a cough with mucus (phlegm). Though not typical, sometimes chest congestion is a sign of COVID-19. This can cause a wet or productive cough ...

Depemokimab is also being evaluated in late-stage studies for eosinophilic granulomatosis with polyangiitis and hyper-eosinophilic syndrome. Sales in GSK’s respiratory portfolio are currently ...